메뉴 건너뛰기
JAMA Oncology
Volumn 1, Issue 6, 2015, Pages 836-838
Vemurafenib use in an infant for high-risk langerhans cell histiocytosis
Author keywords

[No Author keywords available]
Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; SULFONAMIDE; TUMOR MARKER; VEMURAFENIB;
EID: 84965093707     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.0736     Document Type: Letter
Times cited : (95)
References (7)
  • 1
    • 9344224571 scopus 로고    scopus 로고
    • A new clinical score for disease activity in Langerhans cell histiocytosis
    • Donadieu J, Piguet C, Bernard F, et al. A new clinical score for disease activity in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2004;43(7):770-776.
    • (2004) Pediatr Blood Cancer. , vol.43 , Issue.7 , pp. 770-776
    • Donadieu, J.1    Piguet, C.2    Bernard, F.3
  • 2
    • 77956904045 scopus 로고    scopus 로고
    • Recurrent BRAF mutations in Langerhans cell histiocytosis
    • Badalian-Very G, Vergilio J-A, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116(11):1919-1923.
    • (2010) Blood. , vol.116 , Issue.11 , pp. 1919-1923
    • Badalian-Very, G.1    Vergilio, J.-A.2    Degar, B.A.3
  • 3
    • 84876498502 scopus 로고    scopus 로고
    • Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation
    • Haroche J, Cohen-Aubart F, Emile J-F, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2013;121(9):1495-1500.
    • (2013) Blood. , vol.121 , Issue.9 , pp. 1495-1500
    • Haroche, J.1    Cohen-Aubart, F.2    Emile, J.-F.3
  • 4
    • 84899879031 scopus 로고    scopus 로고
    • A LC/MS/MS micro-method for human plasma quantification of vemurafenib: Application to treated melanoma patients
    • Alvarez J-C, Funck-Brentano E, Abe E, Etting I, Saiag P, Knapp A. A LC/MS/MS micro-method for human plasma quantification of vemurafenib: application to treated melanoma patients. J Pharm Biomed Anal. 2014;97:29-32.
    • (2014) J Pharm Biomed Anal. , vol.97 , pp. 29-32
    • Alvarez, J.-C.1    Funck-Brentano, E.2    Abe, E.3    Etting, I.4    Saiag, P.5    Knapp, A.6
  • 5
    • 84899473817 scopus 로고    scopus 로고
    • Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas
    • Bautista F, Paci A, Minard-Colin V, et al. Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas. Pediatr Blood Cancer. 2014;61 (6):1101-1103.
    • (2014) Pediatr Blood Cancer. , vol.61 , Issue.6 , pp. 1101-1103
    • Bautista, F.1    Paci, A.2    Minard-Colin, V.3
  • 6
    • 84897458716 scopus 로고    scopus 로고
    • Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: An open-label, multicentre, safety study
    • Larkin J, Del Vecchio M, Ascierto PA, et al. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol. 2014;15(4):436-444.
    • (2014) Lancet Oncol. , vol.15 , Issue.4 , pp. 436-444
    • Larkin, J.1    Del Vecchio, M.2    Ascierto, P.A.3
  • 7
    • 57849117384 scopus 로고    scopus 로고
    • New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
    • Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45 (2):228-247.
    • (2009) Eur J Cancer. , vol.45 , Issue.2 , pp. 228-247
    • Eisenhauer, E.A.1    Therasse, P.2    Bogaerts, J.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.